Reversible Cardiac Hypertrophy in Pulmonary Arterial Hypertension Treated With High-Dose Epoprostenol
Article in CJC Open (July 2022)
The most recent citing publications are shown below. View all 4 publications that cite this research output on Dimensions.
Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension
Article in BMC Pulmonary Medicine (October 2017)
A comprehensive review on the potential therapeutic benefits of phosphodiesterase inhibitors on cardiovascular diseases
Article in Biomedicine & Pharmacotherapy (August 2017)